NCT03852498已完成3 期
A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects ≤17 Years of Age With Cerebral Adrenoleukodystrophy (CALD)
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 35
- 试验地点
- 16
- 主要终点
- Percentage of Participants Who Were Alive and Have None of the 6 Major Functional Disabilities (MFDs) at Month 24
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of Lenti-D Drug Product (also known as elivaldogene autotemcel or Skysona, hereafter referred to as eli-cel) after myeloablative conditioning with busulfan and fludarabine in participants with CALD. A participant's blood stem cells will be collected and modified (transduced) using the Lenti-D lentiviral vector encoding human adrenoleukodystrophy protein. After modification (transduction) with the Lenti-D lentiviral vector, the cells will be transplanted back into the participant following myeloablative conditioning. Enrollment and treatment in Study ALD-104 have been completed and further enrollment in this study is not expected, although participants follow-up remains ongoing in the long-term follow-up Study LTF-304 (NCT02698579).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- — 至 17 Years（Child）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Informed consent is obtained from a competent custodial parent or guardian with legal capacity to execute a local Institutional Review Board (IRB)/independent ethics committee (IEC) approved consent. Informed assent will be sought from capable participants, in accordance with the directive of the IRB/IEC and with local requirements.
- •Males aged 17 years and younger, at the time of parental/guardian consent and, where appropriate, participant assent.
- •Active CALD as defined by:
- •Elevated very long chain fatty acids (VLCFA) values, and
- •Active central nervous system (CNS) disease established by central radiographic review of brain MRI demonstrating: i) Loes score between 0.5 and 9 (inclusive) on the 34-point scale, and ii) Gadolinium enhancement (GdE) on MRI of demyelinating lesions.
- •NFS < or = 1.
排除标准
- •Prior receipt of an allogeneic transplant or gene therapy.
- •Use of statins, Lorenzo's Oil, or dietary regimens used to lower VLCFA levels. Note: participants must discontinue use of these medications at time of consent.
- •Receipt of an investigational study drug or procedure within 3 months before Screening that might confound study outcomes. Use of investigational study drugs is prohibited throughout the course of the study.
- •Any conditions that make it impossible to perform MRI studies (including allergies to anesthetics or contrast agents).
- •Hematological compromise as evidenced by:
- •Peripheral blood absolute neutrophil count (ANC) count <1500 cells/ cubic millimeter (mm^3), and either
- •Platelet count <100,000 cells/mm^3, or
- •Hemoglobin <10 gram per deciliter (g/dL).
- •Hepatic compromise as evidenced by:
- •Aspartate transaminase (AST) value greater than (>) 2.5 × upper limit of normal (ULN)
- •Alanine transaminase (ALT) value >2.5 × ULN
- •Total bilirubin value >3.0 milligram per deciliter (mg/dL), except if there is a diagnosis of Gilbert's Syndrome and the participant is otherwise stable
- •Baseline estimated glomerular filtration rate <70 milliliter per minute (mL/min)/1.73 square meter (m^2).
- •Cardiac compromise as evidenced by left ventricular ejection fraction <40 percent (%).
- •Immediate family member with a known or suspected Familial Cancer Syndrome.
- •Clinically significant uncontrolled, active bacterial, viral, fungal, parasitic, or prion associated infection.
- •Positive for human immunodeficiency virus type 1 or 2 (HIV-1, HIV-2); hepatitis B virus (HBV); hepatitis C virus (HCV); human T lymphotrophic virus 1 (HTLV-1). (Note that participants who have been vaccinated against HBV [positive for HBV surface antibodies] who are negative for other markers of prior HBV infection [e.g., negative for HBV core Ab] are eligible. Participants with past exposure to HBV [hepatitis B core antibody [HBcAb] -positive and/or hepatitis B e-antigen antibody [HBeAb]-positive] are also eligible for the study provided they have a negative test for HBV DNA. Also note that participants who are positive for anti-hepatitis C Ab are eligible as long as they have a negative hepatitis C viral load).
- •Any clinically significant cardiovascular, hematological, or pulmonary disease, or other disease or condition that would be contraindicated for any of the other study procedures.
- •Absence of adequate contraception for fertile participants.
- •Any contraindications to the use of Granulocyte colony-stimulating factor (G-CSF) or plerixafor during the mobilization of HSCs, and any contraindications to the use of busulfan or fludarabine, including known hypersensitivity to the active substances or to any of the excipients in their formulations.
- •Known hypersensitivity to protamine sulfate.
结局指标
主要结局
Percentage of Participants Who Were Alive and Have None of the 6 Major Functional Disabilities (MFDs) at Month 24
时间窗: At Month 24
The MFDs consisted of loss of communication, cortical blindness, tube feeding, total incontinence, wheelchair dependence, complete loss of voluntary movement. Month-24 MFD-Free survival criteria defined as: alive at 24 months post infusion; have not developed any of the MFDs by 24 months post infusion; have not received rescue cell administration or allo-hematopoietic stem cell transplantation (HSCT) by 24 months post infusion; and have not withdrawn from the study or have not been lost to follow-up by 24 months post infusion.
Percentage of Participants Who Achieved Neutrophil Engraftment After Drug Product Infusion
时间窗: By 42 days post-drug infusion
Neutrophil engraftment is defined as achieving 3 consecutive absolute neutrophil count (ANC) laboratory values of \>= 0.5x10\^9 cells/liter (L) (after initial post-infusion nadir) obtained on different days by 42 days postinfusion of eli-cel (Rel Day 43).
次要结局
- Percentage of Participants Who Experienced >= Grade 2 Acute Graft Versus Host Disease (GVHD) by Month 24(By Month 24)
- Percentage of Participants With Clinical >= Grade 3 Adverse Events (AEs), All Investigational Medicinal Product-related AEs, All Serious Adverse Events (SAEs), and >= Grade 3 Infections(From date of informed consent up to Month 24)
- Duration of In-patient Hospitalizations (Post-Neutrophil Engraftment) up to Month 24(From post-neutrophil engraftment up to Month 24)
- Number of Emergency Room Visits (Post-Neutrophil Engraftment) by Month 24(From Post-Neutrophil Engraftment up to Month 24)
- Overall Survival Rate(At 24 months after Lenti-D drug infusion)
- Percentage of Participants Who Experienced Either Acute (>= Grade 2) or Chronic Graft Versus Host Disease (GVHD) at Month 24(At Month 24)
- Number of Participants Who Achieved Stable NFS at Month 24(At Month 24)
- Percentage of Participants With Loss of Neutrophil Engraftment Post-drug Product Infusion by Month 24(By Month 24)
- Percentage of Participants Without Gadolinium Enhancement (i.e. GdE-) on Magnetic Resonance Imaging (MRI) at Month 24(At Month 24)
- Number of Participants With Change in Neurologic Function Score (NFS) From Baseline to Month 24(Baseline up to Month 24)
- Major Functional Disability (MFD)-Free Survival Rate(At 24 months after Lenti-D drug infusion)
- Time to Platelet Engraftment Post-drug Product Infusion(By Month 24)
- Median Detectable Vector Copy Number (VCN) in Peripheral Blood Cells by Month 6(By Month 6 post-transplant)
- Time to Neutrophil Engraftment (NE) After Drug Product Infusion(By 42 days post-drug infusion)
- Percentage of Participants With Platelet Engraftment by Month 24(By Month 24)
- Percentage of Participants Who Underwent a Subsequent Allo- Hematopoietic Stem Cell Transplantation (HSCT) Infusion by Month 24(By Month 24)
- Percentage of Participants Who Experienced Transplant-related Mortality Through 100 and 365 Days Post-drug Product Infusion(From time of drug product infusion through 100 and 365 days post-drug product infusion)
- Number of Participants With >= Grade 3 Prolonged Cytopenia on or After Rel Day 60 And Rel Day 100(Prolonged cytopenias occurring on or after Rel Day 60 and Rel Day 100 following drug product infusion)
- Median Number of Emergency Room Visits (Post-Neutrophil Engraftment) by Month 24(From Post-Neutrophil Engraftment up to Month 24)
- Percentage of Participants Who Experienced Chronic GVHD by Month 24(By Month 24)
- Percentage of Participants With Potentially Clinically Significant Changes in Laboratory Parameters by Month 24(From Day 1 to Month 24)
- Number of Intensive Care Units (ICU) Stays (Post-neutrophil Engraftment) by Month 24(From post-neutrophil engraftment up to Month 24)
- Number of In-patient Hospitalizations (Post-Neutrophil Engraftment) by Month 24(From Post-Neutrophil Engraftment up to Month 24)
- Median Number of In-patient Hospitalizations (Post-Neutrophil Engraftment) by Month 24(From post-neutrophil engraftment up to Month 24)
- Duration of ICU Stays (Post-neutrophil Engraftment) by Month 24(From post-neutrophil engraftment up to Month 24)
- Number of Participants With Insertional Oncogenesis by Month 24(By Month 24 post-transplant)
- Number of Participants Who Tested Positive and Negative for Vector-Derived Replication Competent Lentivirus (RCL) Detected by Month 24(By Month 24)
研究者
研究点 (16)
Loading locations...
相似试验
进行中（未招募）
1 期
Clinical study to assess the efficacy and safety of gene therapy for the treatment of cerebral adrenoleukodystrophy (CALD).Cerebral Adrenoleukodystrophy (CALD)MedDRA version: 20.0Level: PTClassification code 10051260Term: AdrenoleukodystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2018-001145-14-GBbluebird bio, Inc.35
进行中（未招募）
1 期
Clinical study to assess the efficacy and safety of gene therapy for the treatment of cerebral adrenoleukodystrophy (CALD)Cerebral Adrenoleukodystrophy (CALD)MedDRA version: 20.0Level: PTClassification code 10051260Term: AdrenoleukodystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2018-001145-14-NLbluebird bio, Inc.35
进行中（未招募）
1 期
Clinical study to assess the efficacy and safety of gene therapy for the treatment of cerebral adrenoleukodystrophy.Cerebral Adrenoleukodystrophy (CALD)MedDRA version: 20.0 Level: PT Classification code 10051260 Term: Adrenoleukodystrophy System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2018-001145-14-FRbluebird bio, Inc.20
已完成
3 期
A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects <=17 Years of Age With Cerebral Adrenoleukodystrophy (CALD)NL-OMON54719bluebird bio Inc6
进行中（未招募）
1 期
Clinical study to assess the efficacy and safety of gene therapy for the treatment of cerebral adrenoleukodystrophy (CALD)EUCTR2018-001145-14-DEbluebird bio, Inc.35